-
Je něco špatně v tomto záznamu ?
Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis
P. Rajwa, B. Pradere, G. Gandaglia, RCN. van den Bergh, I. Tsaur, SR. Shim, T. Yanagisawa, E. Laukhtina, K. Mori, H. Mostafaei, F. Quhal, P. Bryniarski, E. Compérat, G. Roubaud, C. Massard, AS. Merseburger, MS. Leapman, DE. Spratt, F. Saad, S....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, metaanalýza, přehledy, systematický přehled
- MeSH
- antagonisté androgenů škodlivé účinky MeSH
- antitumorózní látky * terapeutické užití MeSH
- docetaxel terapeutické užití MeSH
- lidé MeSH
- nádory prostaty * farmakoterapie patologie MeSH
- prospektivní studie MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- přehledy MeSH
- systematický přehled MeSH
CONTEXT: Several recent randomised trials have evaluated the role of combination systemic treatment using androgen deprivation therapy (ADT) plus chemotherapy or an androgen receptor signaling inhibitor (ARSI) in patients with high-risk and/or unfavourable nonmetastatic prostate cancer (nmPC). OBJECTIVE: To assess the outcomes associated with adding combination systemic treatment to primary definitive local therapy in patients with high-risk and/or unfavourable nmPC. EVIDENCE ACQUISITION: We queried the PubMed, Web of Science, and Scopus databases and conference abstracts to identify prospective randomised trials examining the value of adding chemotherapy or an ARSI to ADT and primary local therapy with curative intent for nmPC. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), and failure-free survival (FFS). Secondary endpoints included adverse events (AEs) and pathologic outcomes. EVIDENCE SYNTHESIS: We identified 15 randomised studies, of which nine evaluated chemohormonal and six investigated ARSI-based treatment strategies. In both radical prostatectomy (RP) and radiation therapy (RT) settings, addition of docetaxel to ADT was associated with significantly better CSS (pooled hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.49-0.95; p = 0.025), MFS (pooled HR 0.82, 95% CI 0.71-0.95; p = 0.008), and FFS (pooled HR 0.70, 95% CI 0.62-0.79; p < 0.001); the difference did not meet the conventional level of statistical significance for OS (pooled HR 0.86, 95% CI 0.73-1.01; p = 0.072). For patients treated with RT alone, docetaxel-based combination treatment did not meet the significance threshold set for OS (p = 0.3), CSS (p = 0.072), or MFS (p = 0.079), but the difference for FFS was statistically significant (pooled HR 0.72, 95% CI 0.63-0.84; p < 0.001). On network meta-analyses including RT studies, ARSI + ADT outperformed docetaxel + ADT for survival endpoints and had a more favourable AE profile. CONCLUSIONS: Intensification of systemic therapy with docetaxel or an ARSI in addition to ADT improves oncologic endpoints in high-risk and/or unfavourable nmPC treated with local definitive therapy. The highest efficacy was achieved with ARSI + ADT, specifically in patients treated with RT. PATIENT SUMMARY: Our findings highlight that selected patients with high-risk nonmetastatic prostate cancer benefit from intensification of systemic therapy beyond hormonal treatment.
Department of Medical Oncology Institut Bergonié Bordeaux France
Department of Pathology Hôpital Tenon Sorbonne University Paris 6 Paris France
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology La Croix du Sud Hospital Quint Fonsegrives France
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology St Antonius Hospital Nieuwegein the Netherlands
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Hospital Schleswig Holstein Lübeck Germany
Department of Urology University Hospitals Leuven Leuven Belgium
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Department of Urology Yale School of Medicine New Haven CT USA
Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
Unit of Urology Division of Oncology IRCCS San Raffaele San Raffaele Hospital Milan Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017884
- 003
- CZ-PrNML
- 005
- 20220804134437.0
- 007
- ta
- 008
- 220720s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2022.03.031 $2 doi
- 035 __
- $a (PubMed)35465985
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
- 245 10
- $a Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis / $c P. Rajwa, B. Pradere, G. Gandaglia, RCN. van den Bergh, I. Tsaur, SR. Shim, T. Yanagisawa, E. Laukhtina, K. Mori, H. Mostafaei, F. Quhal, P. Bryniarski, E. Compérat, G. Roubaud, C. Massard, AS. Merseburger, MS. Leapman, DE. Spratt, F. Saad, S. Joniau, AV. D'Amico, A. Briganti, SF. Shariat, G. Ploussard, European Association of Urology Young Academic Urologists Prostate Cancer Working Party
- 520 9_
- $a CONTEXT: Several recent randomised trials have evaluated the role of combination systemic treatment using androgen deprivation therapy (ADT) plus chemotherapy or an androgen receptor signaling inhibitor (ARSI) in patients with high-risk and/or unfavourable nonmetastatic prostate cancer (nmPC). OBJECTIVE: To assess the outcomes associated with adding combination systemic treatment to primary definitive local therapy in patients with high-risk and/or unfavourable nmPC. EVIDENCE ACQUISITION: We queried the PubMed, Web of Science, and Scopus databases and conference abstracts to identify prospective randomised trials examining the value of adding chemotherapy or an ARSI to ADT and primary local therapy with curative intent for nmPC. The primary endpoints were overall survival (OS), cancer-specific survival (CSS), metastasis-free survival (MFS), and failure-free survival (FFS). Secondary endpoints included adverse events (AEs) and pathologic outcomes. EVIDENCE SYNTHESIS: We identified 15 randomised studies, of which nine evaluated chemohormonal and six investigated ARSI-based treatment strategies. In both radical prostatectomy (RP) and radiation therapy (RT) settings, addition of docetaxel to ADT was associated with significantly better CSS (pooled hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.49-0.95; p = 0.025), MFS (pooled HR 0.82, 95% CI 0.71-0.95; p = 0.008), and FFS (pooled HR 0.70, 95% CI 0.62-0.79; p < 0.001); the difference did not meet the conventional level of statistical significance for OS (pooled HR 0.86, 95% CI 0.73-1.01; p = 0.072). For patients treated with RT alone, docetaxel-based combination treatment did not meet the significance threshold set for OS (p = 0.3), CSS (p = 0.072), or MFS (p = 0.079), but the difference for FFS was statistically significant (pooled HR 0.72, 95% CI 0.63-0.84; p < 0.001). On network meta-analyses including RT studies, ARSI + ADT outperformed docetaxel + ADT for survival endpoints and had a more favourable AE profile. CONCLUSIONS: Intensification of systemic therapy with docetaxel or an ARSI in addition to ADT improves oncologic endpoints in high-risk and/or unfavourable nmPC treated with local definitive therapy. The highest efficacy was achieved with ARSI + ADT, specifically in patients treated with RT. PATIENT SUMMARY: Our findings highlight that selected patients with high-risk nonmetastatic prostate cancer benefit from intensification of systemic therapy beyond hormonal treatment.
- 650 _2
- $a antagonisté androgenů $x škodlivé účinky $7 D000726
- 650 12
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a docetaxel $x terapeutické užití $7 D000077143
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a nádory prostaty $x farmakoterapie $x patologie $7 D011471
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Gandaglia, Giorgio $u Unit of Urology/Division of Oncology, IRCCS San Raffaele, San Raffaele Hospital, Milan, Italy
- 700 1_
- $a van den Bergh, Roderick C N $u Department of Urology, St. Antonius Hospital, Nieuwegein, the Netherlands
- 700 1_
- $a Tsaur, Igor $u Department of Urology and Pediatric Urology, University Medical Center, Johannes Gutenberg University, Mainz, Germany
- 700 1_
- $a Shim, Sung Ryul $u Department of Health and Medical Informatics, Kyungnam University College of Health Sciences, Changwon, Republic of Korea
- 700 1_
- $a Yanagisawa, Takafumi $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Bryniarski, Piotr $u Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Compérat, Eva $u Department of Pathology, Hôpital Tenon, Sorbonne University Paris VI, Paris, France
- 700 1_
- $a Roubaud, Guilhem $u Department of Medical Oncology, Institut Bergonié, Bordeaux, France
- 700 1_
- $a Massard, Christophe $u Département des Innovations Thérapeutiques et Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- 700 1_
- $a Merseburger, Axel S $u Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany
- 700 1_
- $a Leapman, Michael S $u Department of Urology, Yale School of Medicine, New Haven, CT, USA
- 700 1_
- $a Spratt, Daniel E $u Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA
- 700 1_
- $a Saad, Fred $u Division of Urology and Urologic Oncology, Centre Hospitalier de Université de Montréal, University of Montreal, Montreal, QC, Canada
- 700 1_
- $a Joniau, Steven $u Department of Urology, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a D'Amico, Anthony V $u Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA, USA
- 700 1_
- $a Briganti, Alberto $u Unit of Urology/Division of Oncology, IRCCS San Raffaele, San Raffaele Hospital, Milan, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA. Electronic address: shahrokh.shariat@meduniwien.ac.at
- 700 1_
- $a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
- 710 2_
- $a European Association of Urology Young Academic Urologists Prostate Cancer Working Party
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 82, č. 1 (2022), s. 82-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35465985 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134430 $b ABA008
- 999 __
- $a ok $b bmc $g 1821805 $s 1169127
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 82 $c 1 $d 82-96 $e 20220422 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20220720
